3D Models of Immunotherapy

免疫疗法的 3D 模型

• 批准号: 9283025
• 负责人: FRANK S HODI
• 金额: $ 57.44万
• 依托单位: HARVARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9283025
• 关键词: Address; Adjuvant; Angiogenic Factor; Animals; Antigen-Presenting Cells; Antigens; Award; Biocompatible Materials; Biological Models; Blocking Antibodies; Blood Vessels; Cancer Vaccines; Cancerous; Cell Communication; Cell Culture Techniques; Cell physiology; Cell surface; Cells; Cellular biology; Cessation of life; Complement; Cytotoxic T-Lymphocyte-Associated Protein 4; Cytotoxic T-Lymphocytes; Dendritic Cells; Development; Devices; Distant; Experimental Models; Failure; Future; Gene Expression; Generations; Human; Human Biology; Immune; Immune response; Immunotherapy; Impairment; In Vitro; Malignant Neoplasms; Modeling; Mus; Neoplasms in Vascular Tissue; Patients; Perfusion; Phase I Clinical Trials; Pre-Clinical Model; Printing; Role; Site; T-Lymphocyte; Testing; Therapeutic; Therapeutic Agents; Tissues; Vaccination; Vaccines; Work; antitumor effect; base; cancer immunotherapy; humanized mouse; immune checkpoint blockade; immune function; immunoregulation; in vitro Model; in vivo; lymph nodes; melanoma; mouse model; neoplastic cell; novel; novel vaccines; preclinical study; response; success; therapeutic vaccine; three-dimensional modeling; tool; trafficking; tumor; vaccination strategy

Cancer immunotherapy is currently providing exciting new treatment options for patients. However, the majority of patients still do not respond to current immunotherapies, and this failure likely results, at least in part, from an inability to generate potent cytotoxic T lymphocyte (CTL) responses against cancer antigens, and the tolerizing effects of the tumors. Therapeutic vaccines may be needed to generate robust CTL responses, and we have recently developed a new biomaterials strategy for vaccination that led to unprecedented ability to eradicate established tumors in preclinical models. However, the development of next generation vaccines based on this concept, and therapeutic cancer vaccines more generally, is significantly impaired by the limitations of current model systems available to explore and test these types of therapies. Preclinical studies typically utilize mouse models, but even humanized mouse models do not capture key aspects of human biology relevant to immunotherapies. Cell culture studies can be used to explore human immune cell biology, but standard human cell culture models do not recreate the 3D, multicellular interactions that direct the immune response against cancer nor the tumor cell-immune cell interactions that dictate vaccination success. This application proposes to create 3D models of human biology that enable one to study key aspects of vaccination. These models will replicate, in vitro, the vaccine site itself, where the immune response to cancer antigens is initiated, and the tumor, where immune cells encounter cancerous cells, and the function of the immune cells is typically down-regulated by the cells within the tumor. In order to thoroughly characterize and validate our approach, we will first create 3D mouse models of the vaccine site and the tumor, as this will allow direct comparison between the 3D in vitro model and the in vivo tissue of the same type. These studies will be key to validate the models. We will then create the human models, using tumor, vascular and immune cells all derived from the same patient. These human models will be used to begin exploring several key issues in therapeutic cancer vaccination, including the role of checkpoint blockade and angiogenic factors on the tumors, and the impact of vaccination intratumorally on the immune cell response. At the completion of this project we will have developed and thoroughly characterized novel, 3D models of both mouse and human biology that will replicate the vaccination site and vascularized tumors. These models will allow us to explore key questions relevant to human cancer immunotherapy, and provide a means to screen the impact of immunomodulatory agents (e.g., various adjuvants) in the future as we and others develop new cancer immunotherapies.

癌症免疫疗法目前为患者提供了令人兴奋的新治疗选择。但是大部分 的患者仍然对目前的免疫疗法没有反应，这种失败可能至少部分是由于 不能产生针对癌抗原的有效细胞毒性T淋巴细胞（CTL）应答， 肿瘤的耐受作用。可能需要治疗性疫苗来产生强有力的CTL应答， 我们最近开发了一种新的疫苗接种生物材料策略，带来了前所未有的能力， 在临床前模型中根除已建立的肿瘤。然而，下一代疫苗的开发 基于这一概念，以及更普遍的治疗性癌症疫苗， 目前可用于探索和测试这些类型的疗法的模型系统的局限性。临床前研究 通常利用小鼠模型，但即使是人源化的小鼠模型也不能捕获人类的关键方面。 与免疫疗法相关的生物学。细胞培养研究可用于探索人类免疫细胞生物学， 但标准的人类细胞培养模型并不能重现3D多细胞相互作用， 也不影响决定疫苗接种成功的肿瘤细胞-免疫细胞相互作用。这 应用程序提出创建人类生物学的3D模型，使人们能够研究 预防针这些模型将在体外复制疫苗位点本身，在那里对癌症的免疫反应 抗原被启动，肿瘤，免疫细胞遇到癌细胞，以及免疫细胞的功能。 免疫细胞通常被肿瘤内的细胞下调。为了彻底描述和 为了验证我们的方法，我们将首先创建疫苗部位和肿瘤的3D小鼠模型，因为这将允许 3D体外模型与体内同类组织的直接比较。这些研究报告将 验证模型的关键。然后，我们将创建人类模型，使用肿瘤，血管和免疫细胞， 来自同一个病人。这些人体模型将用于开始探索几个关键问题， 治疗性癌症疫苗接种，包括检查点阻断和血管生成因子对肿瘤的作用， 以及瘤内接种对免疫细胞应答的影响。在这个项目完成后，我们 将开发并彻底表征小鼠和人类生物学的新颖3D模型， 复制疫苗接种部位和血管化肿瘤。这些模型将使我们能够探索关键问题 为人类肿瘤免疫治疗提供相关的研究，并提供一种筛选免疫调节作用的手段， 代理（例如，各种佐剂），因为我们和其他人在未来开发新的癌症免疫疗法。